Table 2 The usability of treatment outcomes for kidney failure treatment modality decisions according to patients

1.The flexibility of each treatment modality*

Yes = 93 (74%)

No = 20 (16%)

I don’t know = 12 (10%)

2.The survival of each treatment modality after treatment initiation*

Yes = 92 (74%)

No = 11 (9%)

I don’t know = 21 (17%)

3.The effect of each treatment modality on the residual kidney function over time*

Yes = 89 (71%)

No = 19 (15%)

I don’t know = 17 (14%)

4.Patient reported levels of physical functioning on each treatment modality*

Yes = 82 (66%)

No = 30 (24%)

I don’t know = 13 (10%)

5.The effects of each treatment modality on social functioning*

Yes = 81 (65%)

No = 31 (25%)

I don’t know = 12 (10%)

6.Patient survival on each treatment modality*

Yes = 81 (65%)

No = 27 (22%)

I don’t know = 17 (13%)

7.The effects of each treatment modality on personal life*

Yes = 78 (63%)

No = 33 (27%)

I don’t know = 13 (10%)

8.Complication rates related to immunosuppressive drugs after transplantation*

Yes = 76 (61%)

No = 34 (27%)

I don’t know = 15 (12%)

9.Hospitalisation rates for each treatment modality after initiation*

Yes = 74 (60%)

No = 36 (29%)

I don’t know = 14 (11%)

10.Event rates for cardiovascular complications on each treatment modality*

Yes = 73 (58%)

No = 29 (24%)

I don’t know = 23 (18%)

11.Patient reported levels of pain on each treatment modality*

Yes = 67 (54%)

No = 43 (35%)

I don’t know = 14 (11%)

12.Vascular access survival in HD*

Yes = 67 (54%)

No = 35 (28%)

I don’t know = 23 (18%)

13.Patient reported levels of fatigue on each treatment modality*

Yes = 66 (53%)

No = 40 (32%)

I don’t know = 19 (15%)

14.PD peritonitis rates*

Yes = 64 (52%)

No = 41 (33%)

I don’t know = 18 (15%)

15.Patient reported levels of depression on each treatment modality*

Yes = 54 (43%)

No = 54 (43%)

I don’t know = 17 (14%)